Drug Watch

October 22nd 2024

Here's what you need to know about the latest FDA-approved schizophrenia treatment.

October 14th 2024

Learn more about the new positive efficacy, safety, tolerability data from the phase 3 SOLARIS trial, which were presented at the 37th Annual European College of Neuropsychopharmacology Congress.

October 11th 2024

New data shared at ECNP Congress informs clinicians of how best to switch patients from a once-monthly subcutaneous injection of Perseris to risperidone (Uzedy).

October 9th 2024

The FDA has granted Fast Track designation to liafensine for the treatment of patients with treatment-resistant depression.